BioScrip Announces U.S. Congress Passage of Medicare Home Infusion Transition Benefit, Effective 2019

DENVER--(BUSINESS WIRE)--BioScrip, Inc. (NASDAQ:BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today announced that the U.S. Congress today passed the Medicare Home Infusion Therapy Access Act of 2017 (H.R. 3163/S. 1738) as part of the Continuing Resolution. The legislation provides for a transitional benefit payment, beginning January 1, 2019, for Medicare Part B home infusion services, which will continue until the commencement of a permanent payment structure under the 21st Century Cures Act, currently expected to take effect in 2021.